INEX Pharmaceuticals is creating the Liposomal formulation of Vincristine for the treatment of reversed insistent non-Hodgkin’s lymphoma – NHL as well as some other cancers.  Onco TCS is the proprietary drug prepared from the most commonly used off-patent anti-cancer drug popularly known as lipid vincristine summarized in the INEX Liposomal drug delivery. Onco TCS – Transmembrane Carrier System is Vincristine, vincacine, vincristine Sulfate Liposomes for the injection – VSLI.

Some 119 patients having insistent NHL were treated who did not respond to their earlier therapies or had retorted but later reversed, during the concluded multi-centre fundamental phase II and phase III clinical trials for the Onco TCS. This specific trial showed nearly 25 percent response rate in general. There is no typical treatment for the patients having the insistent NHL that has reversed after minimum a couple of earlier treatment procedures, at of now.

According to the medical terminology, the Onco TCS has exclusively been designed to provide extended blood circulation, tumor accretion as well as the extended drug discharge at the site of the cancer. Such features are meant to improve the efficacy and minimize the side effects of the summarized drug. Liposomal vincristine is expected of having several benefits as compared with the current normal preparations of vincristine as the TCS technology’s use facilitates the vincristine to flow in the blood longer, accrue in the tumor and be discharged over the prolonged phase of time at the site of the tumor. By applying the TCS technique to any agent including vincristine, has the capability of improving the efficiency and reduce the side effects of the agent.